Oppenheimer Rates Inhibikase Therapeutics (IKT) buy

Oppenheimer maintains a buy rating on Inhibikase Therapeutics, setting a $5.00 price target, a 199.40% upside from the current price.

By EarningsIQ Research Desk · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 16, 2026, 9:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Oppenheimer rated Inhibikase Therapeutics, Inc. ($IKT) "buy" with a $5 price target on June 10, 2026.

Since the rating, $IKT is up 1.2% after 1 week, up 22.9% after 1 month and down 0.6% to date (from the $1.66 close on Jun 10, 2026).

IKT Inhibikase Therapeutics, Inc.

$1.65 -15.38% year to date

Daily close · Oct 16, 2026

Key Points

Oppenheimer reiterated its buy rating on Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) with a $5.00 price target on June 10, 2026.
Oppenheimer's $5 price target implies 199.40% upside from Inhibikase Therapeutics, Inc.'s ($IKT) current $1.67 share price.
Inhibikase Therapeutics trades at $1.67 per share with a market cap of approximately $220.5 million and a beta of 0.974.
Insider transactions included significant share purchases by CEO Mark Iwicki and President Christopher Cabell on January 5, 2026.

Get $IKT trade alerts by text

We text you when insiders, Congress or big funds trade $IKT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Inhibikase Therapeutics, Inc. alert may contain errors. Disclosures

Oppenheimer has reiterated its buy rating for Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) with a price target of $5.00. This update was announced on June 10, 2026, as the stock trades at about $1.67.

Other Institutional Activity in Inhibikase Therapeutics

In the realm of institutional investments, BlackRock, Inc. increased its holdings significantly by 2,997,859 shares, bringing its total to 6,303,433 shares valued around $10.59 million. Trails Edge Capital Partners, LP also boosted its position, adding 1,879,221 shares to reach a total of 8,057,345 shares worth approximately $13.54 million. On the other hand, Adar1 Capital Management, LLC reduced its stake by 1,457,377 shares, ending with 6,606,572 shares valued at about $11.10 million.

Inhibikase Therapeutics, Inc. Stock Down 27.4%

Shares of Inhibikase Therapeutics, Inc. trade near $1.67 on the NasdaqCM. The company has a market cap of roughly $220.5 million and a beta of 0.974, indicating its stock price is less volatile than the market average. The stock's 52-week range is between $1.33 and $2.26, with a 50-day moving average of $1.78 and a 200-day moving average of $1.70. The company shows a strong liquidity position with a current ratio of 30.143 and a quick ratio of 29.827.

12-month forecast

$IKT price target

Inhibikase Therapeutics, Inc. daily closes and this analyst's $5 target. Not advice.

Analysts Set New Price Targets

On June 10, 2026, Oppenheimer initiated coverage with a buy rating and a $5.00 price target. Earlier this year, Ladenburg Thalmann also started coverage with a buy rating and a $4.00 target on March 4, 2026. B of A Securities initiated a buy rating with a $6.00 target on January 21, 2026. Overall, the consensus recommendation is a strong buy, with a mean target price of $5.88 based on eight analyst opinions.

Insider Buying and Selling at Inhibikase Therapeutics, Inc.

Significant insider activity was noted earlier this year. On January 5, 2026, CEO Mark Iwicki purchased 4,982,706 shares, and President Christopher Cabell acquired 900,117 shares. These transactions were not part of a pre-planned trading program.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., based in Wilmington, Delaware, is a clinical-stage biotechnology company focused on developing treatments for cardiopulmonary diseases. Its primary product, IKT-001, is a novel oral prodrug targeting pulmonary arterial hypertension. The company is engaged in a Phase 3 clinical trial to evaluate the drug's effectiveness. Led by CEO Mark T. Iwicki, Inhibikase has 35 employees and is committed to advancing its pipeline of therapeutic candidates.

Bottom Line

Investors are keeping a close eye on Inhibikase Therapeutics as Oppenheimer's reiterated buy rating and $5.00 price target reflect confidence in the company's potential. The stock's current price and strong insider buying activity could indicate optimism about its future prospects. As always, it's important to remember that analyst ratings and 13F filings are based on historical data and may not reflect current market conditions.